Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | PRKCQ | Q04759 | 13/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PRKCH | P24723 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199369 | 0.88 | PRKCQ (0.64) | PRKCQPRKCDPDE4BPRKCHPRKCE | |
| SCHEMBL4194592 | 0.83 | PRKCQ (0.76) | EGFRERBB2PRKCQPRKCDABCG2 | |
| SCHEMBL4193621 | 0.82 | EGFR (0.51) | EGFRERBB2PRKCQABCG2 | |
| SCHEMBL5473022 | 0.81 | PRKCQ (0.65) | PRKCQPRKCDABCG2PRKCHPRKCE | |
| SCHEMBL4182703 | 0.80 | PRKCQ (0.60) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL4196893 | 0.78 | PRKCQ (0.60) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL4190265 | 0.78 | EGFR (0.52) | EGFRERBB2PRKCQ | |
| SCHEMBL2983759 | 0.77 | PRKCQ (0.61) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL2985945 | 0.76 | PRKCQ (0.59) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL2980130 | 0.76 | PRKCQ (0.57) | PRKCQPRKCDPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027093-A2 | SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2009-02-25 | — | — | EP | claimed |
| WO-2007146323-A2 | SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-12-21 | — | — | WO | claimed |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | WYETH | 2007-12-13 | — | — | US | claimed |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | WYETH | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K6 | EGFR 2704/4885ERBB2 1345/4885PRKCQ 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.